There are other yet unidentified factors, and high-throughput protein–protein interaction screening methods are needed to search for TCF7L2 interacting protein and to further elucidate the underlying mechanisms for EGLN2 silencing in pancreatic cancer. Here, EGLN2 is linked to pancreatic neoplasm.